390 related articles for article (PubMed ID: 8447358)
1. Effects of desogestrel on carbohydrate metabolism.
Shoupe D
Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1041-7. PubMed ID: 8447358
[TBL] [Abstract][Full Text] [Related]
2. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
Godsland IF; Crook D; Devenport M; Wynn V
Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
[TBL] [Abstract][Full Text] [Related]
3. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
[TBL] [Abstract][Full Text] [Related]
4. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
5. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
[TBL] [Abstract][Full Text] [Related]
6. Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives.
Spellacy WN
Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):732-4. PubMed ID: 7039318
[TBL] [Abstract][Full Text] [Related]
7. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
[TBL] [Abstract][Full Text] [Related]
8. [Influence of progestins on adverse effects of oral contraceptives].
Wynn V
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
[TBL] [Abstract][Full Text] [Related]
9. Effect of oral contraceptive progestins on serum copper concentration.
Berg G; Kohlmeier L; Brenner H
Eur J Clin Nutr; 1998 Oct; 52(10):711-5. PubMed ID: 9805216
[TBL] [Abstract][Full Text] [Related]
10. The effects on hemostasis of oral contraceptives containing desogestrel.
Stubblefield PG
Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1047-52. PubMed ID: 8447359
[TBL] [Abstract][Full Text] [Related]
11. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
Crook D; Godsland IF; Wynn V
Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
[TBL] [Abstract][Full Text] [Related]
12. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
[TBL] [Abstract][Full Text] [Related]
13. The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.
Spellacy WN; Ellingson AB; Tsibris JC
Fertil Steril; 1989 Jan; 51(1):71-4. PubMed ID: 2642814
[TBL] [Abstract][Full Text] [Related]
14. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women.
Nader S; Riad-Gabriel MG; Saad MF
J Clin Endocrinol Metab; 1997 Sep; 82(9):3074-7. PubMed ID: 9284746
[TBL] [Abstract][Full Text] [Related]
15. Six-month carbohydrate metabolism studies in women using oral contraceptives containing gestodene and ethinyl estradiol.
Spellacy WN; Tsibris JC; Hunter-Bonner DL; Smalling S; Chez RA; Angel JL; O'Brien WF
Contraception; 1992 Jun; 45(6):533-9. PubMed ID: 1617962
[TBL] [Abstract][Full Text] [Related]
16. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
Rosing J; Middeldorp S; Curvers J; Christella M; Thomassen LG; Nicolaes GA; Meijers JC; Bouma BN; Büller HR; Prins MH; Tans G
Lancet; 1999 Dec; 354(9195):2036-40. PubMed ID: 10636369
[TBL] [Abstract][Full Text] [Related]
17. Effect of desogestrel-containing oral contraceptives on vascular reactivity and catecholamine levels.
Arangino S; Cagnacci A; Angiolucci M; Longu G; Melis GB; Volpe A
Contraception; 1998 Nov; 58(5):289-93. PubMed ID: 9883384
[TBL] [Abstract][Full Text] [Related]
18. Estrogen and progestin components of oral contraceptives: relationship to vascular disease.
Carr BR; Ory H
Contraception; 1997 May; 55(5):267-72. PubMed ID: 9220222
[TBL] [Abstract][Full Text] [Related]
19. The metabolic impact of oral contraceptives.
Krauss RM; Burkman RT
Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1177-84. PubMed ID: 1415443
[TBL] [Abstract][Full Text] [Related]
20. Clinical and metabolic study of a new pill containing 20 mcg ethinylestradiol plus 0.150 mg desogestrel.
Fioretti P; Fruzzetti F; Navalesi R; Ricci C; Miccoli R; Cerri M; Orlandi MC; Melis GB
Contraception; 1987 Mar; 35(3):229-43. PubMed ID: 2956055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
